Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation

Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2011, Pages 679-686

  Long Boyle, Janel ^a,b   Huang, Jiayin ^c   Rydholm, Nancy ^b   Smith, Angela ^b   Orchard, Paul ^b   Tolar, Jakub ^b   Jacobson, Pamala ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

Clofarabine; hematopoietic cell transplantation; inherited metabolic disorders; pediatrics; pharmacokinetics

Indexed keywords

ALEMTUZUMAB; CLOFARABINE; MELPHALAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BODY WEIGHT; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INBORN ERROR OF METABOLISM; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION;

ADENINE NUCLEOTIDES; ADOLESCENT; ADULT; ARABINONUCLEOSIDES; AREA UNDER CURVE; BODY SURFACE AREA; BODY WEIGHT; BRAIN DISEASES, METABOLIC, INBORN; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MINNESOTA; MODELS, BIOLOGICAL; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 79955549083     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372519     Document Type: Article

References (38)

1. Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis. 1995 ; 18: 413-429
2. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 2003 ; 31: 229-239 (Pubitemid 36336225)
3. Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immunopathol. 2004 ; 26: 119-132 (Pubitemid 40021961)
4. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005 ; 352: 2069-2081 (Pubitemid 40664308)
5. Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004 ; 104: 881-888 (Pubitemid 38970588)
6. Krivit W, Aubourg P, Shapiro E, Peters C. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr Opin Hematol. 1999 ; 6: 377-382 (Pubitemid 29503144)
7. Griffin DE, Moser HW, Mendoza Q, Moench TR, O'Toole S, Moser AB. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol. 1985 ; 18: 660-664 (Pubitemid 16085160)
8. Eichler F, Van Haren K. Immune response in leukodystrophies. Pediatr Neurol. 2007 ; 37: 235-244 (Pubitemid 47446159)
9. Awaya T, Kato T, Niwa A, et al. Successful cord blood transplantation using a reduced-intensity conditioning regimen for advanced childhood-onset cerebral adrenoleukodystrophy. Pediatr Transplant. :
10. Barba P, Pinana JL, Valcarcel D, et al. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009 ; 15: 1439-1446
11. Bonate PL, Arthaud L, Cantrell WR, Stephenson K, Secrist JA, Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006 ; 5: 855-863 (Pubitemid 44480539)
12. Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009 ; 78: 1351-1359
13. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 2000 ; 96: 3537-3543
14. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 1991 ; 51: 2386-2394
15. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl) adenine. Cancer Res. 1996 ; 56: 3030-3037
16. Gandhi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol. 2006 ; 18: 584-590 (Pubitemid 44427632)
17. Cambridge, Mass: Genzyme Corporation ; 2008 :
18. Hijiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 ; 23: 2259-2264
19. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 ; 21: 1167-1173 (Pubitemid 46594149)
20. Berg SL, Bonate PL, Nuchtern JG, et al. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res. 2005 ; 11: 5981-5983 (Pubitemid 41170329)
21. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 ; 102: 2379-2386 (Pubitemid 37193573)
22. Bonate PL, Craig A, Gaynon P, et al. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 ; 44: 1309-1322 (Pubitemid 39391490)
23. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 ; 103: 784-789 (Pubitemid 38129533)
24. Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003 ; 9: 6335-6342 (Pubitemid 38031817)
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-41
26. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr. 1985 ; 106: 522-526 (Pubitemid 15140671)
27. Gandhi V, Chen W, Ayres M, Rhie JK, Madden TL, Newman RA. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother Pharmacol. 2002 ; 50: 85-94 (Pubitemid 34969502)
28. Chen N, Aleksa K, Woodland C, Rieder M, Koren G. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol. 2006 ; 21: 160-168 (Pubitemid 43115865)
29. King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol. 2006 ; 69: 346-353 (Pubitemid 43048921)
30. Elwi AN, Damaraju VL, Kuzma ML, et al. Transepithelial fluxes of adenosine and 2′-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3. Am J Physiol Renal Physiol. 2009 ; 296: F1439 - F1451
31. Damaraju S, Zhang J, Visser F, et al. Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. Pharmacogenet Genomics. 2005 ; 15: 173-182 (Pubitemid 40569904)
32. Badagnani I, Chan W, Castro RA, et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 2005 ; 5: 157-165 (Pubitemid 40852217)
33. Bonin M, Pursche S, Bergeman T, et al. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone Marrow Transplant. 2007 ; 39: 201-206
34. Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, Miller JS, Wagner JE, McGlave PB, Jacobson PA. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant. :
35. Boelens JJ, Wynn RF, O'Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007 ; 40: 225-233 (Pubitemid 47108465)
36. Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant. 2008 ; 42 (suppl 1). S49 - S52
37. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003 ; 9: 519-528 (Pubitemid 38351796)
38. Product Information: Fludara (R) (fludarabine phosphate) for Injection. Richmond, Calif: Berlex Laboratories ; 2002 :